ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Veliparib
Drug: Placebo to veliparib
Drug: Paclitaxel

First Posted Date: 2014-04-08

Last Posted Date: 2020-11-17

Lead Sponsor: AbbVie

Target Recruit Count: 970

Registration Number: NCT02106546

Locations: 🇺🇸
Winship Cancer Institute of Emory University /ID# 124061, Atlanta, Georgia, United States
🇺🇸
Parkland Health and Hosp Syste /ID# 128518, Dallas, Texas, United States
🇺🇸
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 128385, Dallas, Texas, United States

and more 222 locations

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: Nivolumab
Drug: Telisotuzumab vedotin
Drug: Osimertinib
Drug: Erlotinib

First Posted Date: 2014-03-28

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 237

Registration Number: NCT02099058

Locations: 🇺🇸
University of California, Los Angeles /ID# 148295, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital /ID# 129804, Boston, Massachusetts, United States
🇺🇸
Duke Cancer Center /ID# 123763, Durham, North Carolina, United States

and more 33 locations

A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Phase 1

Withdrawn

Conditions: Relapsed/Refractory Non-Hodgkin's Lymphoma

Interventions: Drug: [14C]ABT-199 (GDC-0199)

First Posted Date: 2014-03-26

Last Posted Date: 2014-08-13

Lead Sponsor: AbbVie

Registration Number: NCT02095574

Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

Terminated

Conditions: Moderate to Severe Ulcerative Colitis

First Posted Date: 2014-03-20

Last Posted Date: 2017-02-23

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02092389

A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis

Phase 2

Completed

Conditions: Knee Osteoarthritis
Medial Compartment Knee Osteoarthritis

Interventions: Biological: ABT-981
Other: Placebo

First Posted Date: 2014-03-14

Last Posted Date: 2019-08-28

Lead Sponsor: AbbVie

Target Recruit Count: 350

Registration Number: NCT02087904

A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma

Withdrawn

Conditions: Crohn's Disease
Hepatosplenic T-Cell Lymphoma
Ulcerative Colitis (UC)

First Posted Date: 2014-03-14

Last Posted Date: 2019-11-22

Lead Sponsor: AbbVie

Registration Number: NCT02087878

Locations: 🇮🇹
AOU Pisana /ID# 208952, Pisa, Italy

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Phase 3

Withdrawn

Conditions: Hypogonadism
Testosterone Deficiency

Interventions: Drug: ABT-SLV176

First Posted Date: 2014-03-10

Last Posted Date: 2014-06-02

Lead Sponsor: AbbVie

Registration Number: NCT02082197

Locations: 🇺🇸
Site Reference ID/Investigator# 124395, Wichita, Kansas, United States
🇺🇸
Site Reference ID/Investigator# 125782, Mesa, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 123948, Anaheim, California, United States

and more 39 locations

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Phase 3

Completed

Conditions: Advanced Parkinson's Disease

Interventions: Drug: ABT-SLV187

First Posted Date: 2014-03-10

Last Posted Date: 2021-05-12

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT02082249

Locations: 🇨🇳
Linkou Chang Gung Memorial Ho /ID# 102297, Taoyuan City, Taiwan
🇯🇵
Osaka University Hospital /ID# 108335, Suita-shi, Osaka, Japan
🇯🇵
National Center of Neurology and Psychiatry /ID# 98664, Kodaira, Tokyo, Japan

and more 4 locations

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C
Hepatitis C Virus

Interventions: Drug: ABT-450/ritonavir (r)
Drug: ABT-530
Drug: Ribavirin (RBV)

First Posted Date: 2014-02-21

Last Posted Date: 2018-02-22

Lead Sponsor: AbbVie

Target Recruit Count: 10

Registration Number: NCT02068222

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Adalimumab
Drug: Placebo

First Posted Date: 2014-02-19

Last Posted Date: 2021-02-18

Lead Sponsor: AbbVie

Target Recruit Count: 514

Registration Number: NCT02065570

Locations: 🇺🇸
Texas Digestive Disease Consultants - Dallas /ID# 138121, Dallas, Texas, United States
🇺🇸
University of Chicago DCAM /ID# 119077, Chicago, Illinois, United States
🇺🇸
Atlanta Gastro Assoc /ID# 119065, Atlanta, Georgia, United States

and more 140 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy